Patient-reported outcomes from the JADE COMPARE randomised phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.

Jacob Pontoppidan ThyssenG YosipovitchC PaulShawn G KwatraC-Y ChuM DiBonaventuraC FeeneyF ZhangD MyersR RojoH Valdez

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)

Significant improvements in PROs were demonstrated with both abrocitinib doses versus placebo, and abrocitinib 200 mg provided numerically greater effects compared with dupilumab, in patients with moderate-to-severe AD.

Keyphrases

atopic dermatitis
patient reported outcomes
double blind
open label
placebo controlled
high intensity
clinical trial
early onset
phase iii
study protocol
drug induced
randomized controlled trial